Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.
|Slideshows|March 4, 2015
Monthly Roundup: Top 6 Psychiatry Articles in February
Author(s)Psychiatric Times Editors
Editors' choices of noteworthy psychiatry blogs, CMEs, research studies, cases, and books from around the Web.
Advertisement
The following is a list of editors' choices of noteworthy articles published in February. Mentions are not endorsements.Sources:Shrink Rap: Are There Ways to Lessen the Violation That People Feel After Psychiatric Hospitalizations?Shrinks: The Untold Story of PsychiatryDelusional and Aggressive, While Playing the LotteryA Practical Update on Neuroimaging for Psychiatric DisordersTears of Ishtar: Women's Mental Health in IraqNeuroanatomical Characteristics Associated With Response to Dorsal Anterior Cingulotomy for Obsessive-Compulsive Disorder
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
3
FDA Shelves Fast-Track Drug Review Initiative
4
Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and Schizophrenia
5